微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 0.83% | 132.05% | -78.04% | 90/157 | 0.06% | 泽璟制药 | 44.02% | 行业排名> |
| 2025-12-31 | 3.78% | 122.8% | 690.63% | 69/157 | -4.46% | 泽璟制药 | 45.29% | 行业排名> |
| 2025-09-30 | -0.64% | 92.34% | 88.3% | 108/157 | 1.31% | 兴齐眼药 | 38.62% | 行业排名> |
| 2025-06-30 | -5.47% | -42.82% | -111.2% | 131/157 | 0.3% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-03-31 | -2.59% | -38.5% | 84.38% | 132/157 | -0.34% | 翰宇药业 | 18.95% | 行业排名> |
| 2024-12-31 | -16.58% | -240.45% | -98.33% | 127/157 | -9.62% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-09-30 | -8.36% | -2596.77% | -118.28% | 131/157 | 4.28% | 百利天恒 | 181.27% | 行业排名> |
| 2024-06-30 | -3.83% | -1220.69% | -104.81% | 129/157 | 2.69% | 百利天恒 | 186.1% | 行业排名> |
| 2024-03-31 | -1.87% | -314.94% | 61.6% | 127/157 | 2.35% | 百利天恒 | 186.89% | 行业排名> |
| 2023-12-31 | -4.87% | 34.01% | -1470.97% | 117/157 | -1% | 百利天恒 | 188.56% | 行业排名> |
| 2023-09-30 | -0.31% | 58.11% | -6.9% | 116/157 | 2.36% | 小方制药 | 41.8% | 行业排名> |
| 2023-06-30 | -0.29% | 93.01% | -133.33% | 116/157 | 1.48% | 拓新药业 | 20.51% | 行业排名> |
| 2023-03-31 | 0.87% | 480% | 111.79% | 96/157 | 1.37% | 拓新药业 | 19.87% | 行业排名> |
| 2022-12-31 | -7.38% | 9.56% | -897.3% | 121/157 | 0.79% | 拓新药业 | 19.91% | 行业排名> |
| 2022-09-30 | -0.74% | 9.76% | 82.17% | 113/157 | 2.86% | 小方制药 | 55.57% | 行业排名> |
| 2022-06-30 | -4.15% | -99.52% | -2866.67% | 129/157 | 2.21% | 福元医药 | 25.41% | 行业排名> |
| 2022-03-31 | 0.15% | 121.74% | 101.84% | 110/157 | 1.59% | 小方制药 | 34.81% | 行业排名> |
| 2021-12-31 | -8.16% | 27.21% | -895.12% | 126/157 | 0.84% | 退市金泰 | 10.74% | 行业排名> |
| 2021-09-30 | -0.82% | 82.95% | 60.58% | 115/157 | 4.46% | ST人福 | 6.82% | 行业排名> |
| 2021-06-30 | -2.08% | 44.83% | -201.45% | 121/157 | 2.99% | 小方制药 | 71.99% | 行业排名> |
| 2021-03-31 | -0.69% | 28.87% | 93.84% | 111/157 | 2.49% | 汇宇制药 | 39.25% | 行业排名> |
| 2020-12-31 | -11.21% | -39.6% | -133.06% | 120/157 | 3.8% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-09-30 | -4.81% | -13.71% | -27.59% | 104/157 | 3.13% | 哈三联 | 27.17% | 行业排名> |
| 2020-06-30 | -3.77% | 16.59% | -288.66% | 117/157 | 4.28% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-03-31 | -0.97% | 43.6% | 87.92% | 93/157 | 2.23% | 中哲精化 | 45.32% | 行业排名> |
| 2019-12-31 | -8.03% | 44.62% | -89.83% | 120/157 | 2.57% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-09-30 | -4.23% | 25% | 6.42% | 100/157 | 7.58% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-06-30 | -4.52% | 11.2% | -162.79% | 109/157 | 5.02% | 奥赛康 | 35% | 行业排名> |
| 2019-03-31 | -1.72% | -196.55% | 88.14% | 101/157 | 2.45% | 奥赛康 | 28.15% | 行业排名> |
| 2018-12-31 | -14.5% | -77.05% | -157.09% | 127/157 | 7.16% | 宏源药业 | 21.91% | 行业排名> |
| 2018-09-30 | -5.64% | -222.29% | -10.81% | 97/157 | 7.21% | 奥赛康 | 9.7% | 行业排名> |
| 2018-06-30 | -5.09% | -51.49% | -777.59% | 101/157 | 4.63% | 奥赛康 | 40.69% | 行业排名> |
| 2018-03-31 | -0.58% | 63.52% | 92.92% | 95/157 | 2.57% | 信立泰 | 25.93% | 行业排名> |
| 2017-12-31 | -8.19% | 84.7% | -368% | 118/157 | 9.62% | 昂利康 | 15.91% | 行业排名> |
| 2017-09-30 | -1.75% | 93.59% | 47.92% | 94/157 | 8.31% | 奥赛康 | 12.08% | 行业排名> |
| 2017-06-30 | -3.36% | -44.83% | -111.32% | 100/157 | 5.56% | 一品红 | 31.62% | 行业排名> |
| 2017-03-31 | -1.59% | -30.33% | 97.03% | 85/157 | 2.1% | 丽珠集团 | 49.43% | 行业排名> |
| 2016-12-31 | -53.52% | -1190.02% | -95.9% | 108/157 | 6.05% | 中哲精化 | 54.24% | 行业排名> |
| 2016-09-30 | -27.32% | -781.3% | -1077.59% | 79/157 | 5.64% | 华东医药 | 7.2% | 行业排名> |
| 2016-06-30 | -2.32% | -230.34% | -90.16% | 85/157 | 3.52% | ST南新 | 81.7% | 行业排名> |
| 2016-03-31 | -1.22% | -325.93% | -124.85% | 78/157 | 2.69% | 德展健康 | 29.5% | 行业排名> |